Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-C52H8 | Cynomolgus | Cynomolgus IL-2 R alpha / CD25 Protein, His Tag (MALS verified) |  |
|
|
| ILA-H82F9 | Human | Biotinylated Human IL-2 R alpha / CD25 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| ILA-C52H4 | Canine | Canine IL-2 R alpha / CD25 Protein, His Tag |  |
|
|
| ILA-M52H9 | Mouse | Mouse IL-2 R alpha / CD25 Protein, His Tag |  |
|
|
| ILA-H82E6 | Human | Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade |  |
|
|
| ILA-H52H9 | Human | Human IL-2 R alpha / CD25 Protein, His Tag |  |
|
|
| ILA-H5251 | Human | Human IL-2 R alpha / CD25 Protein, Fc Tag (MALS verified) |  |
|
|
Biotinylated Human IL-2 R alpha, His,Avitag, premium grade (Cat. No. ILA-H82E6) inhibits the IL-2-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.57-0.81 µg/mL (Routinely tested).
Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free with an affinity constant of 29.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
| Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Rejection of organ transplantation | F. Hoffmann-La Roche Ag | 1997-12-10 | Rejection of organ transplantation; Behcet Syndrome; Melanoma; Leukemia, T-Cell; Lymphoma; Rejection in heart transplantation; Thrombocytopenia; Uveitis; Iritis; Asthma; Colitis, Ulcerative; Uveitis, Anterior; Anemia, Aplastic; Breast Neoplasms; Psoriasis; Retinal Diseases; Multiple Sclerosis, Relapsing-Remitting; Carcinoma, Ductal; Radiation Injuries; Arthritis, Juvenile; Multiple Sclerosis; Red-Cell Aplasia, Pure; Anemia, Diamond-Blackfan; Myelodysplastic Syndromes; HTLV-I Infections; Inflammatory Bowel Diseases; Gastrointestinal Diseases; Leukemia; Diabetes Mellitus, Type 1; Granulomatosis with Polyangiitis; HIV Infections | Details |
| Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | United States | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Uveitis; Lymphoma, Non-Hodgkin; Emphysema; Pulmonary Disease, Chronic Obstructive; Primary Myelofibrosis; Colitis, Ulcerative; Anemia, Aplastic; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Hodgkin Disease; Hemoglobinuria, Paroxysmal; Keratoplasty rejection; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Nemvaleukin alfa | RDB-1419; RDB-1450; ALKS-4230 | Phase 3 Clinical | Alkermes Plc | Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma | Details |
| Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
| PT-101 | PT-101; MK-6194; PT101 | Phase 2 Clinical | Pandion Therapeutics | Lupus Erythematosus, Systemic; Colitis, Ulcerative; Vitiligo; Dermatitis, Atopic | Details |
| LMB-2 | LMB-2; LMB-2a | Phase 2 Clinical | National Cancer Institute | Leukemia; Skin Melanoma; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, T-Cell | Details |
| Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Adc Therapeutics Sa, Genmab A/S | Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Myeloproliferative Disorders; Pancreatic Neoplasms; Hodgkin Disease; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck | Details |
| Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Graft vs Host Disease | Details | |
| 90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous | Details | |
| Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic | Details |
| Vopikitug | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| BA-1106 | TS-1904; BA-1106; RR-102 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| XmAb-564 | XmAb-564; XmAb564; XmAb-27564 | Phase 1 Clinical | Xencor Inc | Autoimmune Diseases; Psoriasis; Dermatitis, Atopic | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| 9MW-3911 | 9MW3911; 9MW-3911 | Phase 1 Clinical | Nanjing Nuo Aixin Biotechnology Co Ltd | Neoplasms | Details |
| In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
| BMS-986326 | BMS-986326 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Dermatitis, Atopic | Details |
This web search service is supported by Google Inc.
A-Z
